The FDA on December 18, 2024, approved RYONCIL®, an allogeneic bone marrow-derived Mesenchymal Stromal Cell (MSC) therapy, for Steroid-Refractory acute Graft Versus Host Disease (SR-aGVHD) in pediatric patients 2 months of age and older. RYONCIL® is the first FDA-approved MSC therapy and is a product of Mesoblast, Inc.
Bottom Ad
Advertisement
Subscribe
